Sigurdur Y Kristinsson
Overview
Explore the profile of Sigurdur Y Kristinsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
5320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oskarsson J, Rognvaldsson S, Thorsteinsdottir S, Long T, Olafsson A, Eythorsson E, et al.
Blood Cancer J
. 2024 Dec;
14(1):221.
PMID: 39695077
Light-chain (LC) monoclonal gammopathy of undetermined significance (MGUS) is a precursor of multiple myeloma (MM) and related conditions. LC-MGUS is characterized by free light-chain (FLC) levels outside defined reference intervals,...
2.
Hermouet S, Mennesson N, Allain-Maillet S, Bigot-Corbel E, Olafsson A, Vidarsson B, et al.
Hemasphere
. 2024 Dec;
8(12):e70053.
PMID: 39670186
No abstract available.
3.
Rognvaldsson S, Oskarsson J, Thorsteinsdottir S, Hultcrantz M, Palmason R, Sverrisdottir I, et al.
Hemasphere
. 2024 Nov;
8(11):e70046.
PMID: 39564537
Monoclonal gammopathy of undetermined significance (MGUS) is the precursor of multiple myeloma (MM) and related disorders. MGUS is characterized by asymptomatic paraproteinemia. In some cases, multiple paraproteins can be identified...
4.
Went M, Duran-Lozano L, Halldorsson G, Gunnell A, Ugidos-Damboriena N, Law P, et al.
Nat Commun
. 2024 Aug;
15(1):6644.
PMID: 39103364
Multiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling...
5.
Ghobrial I, Gormley N, Kumar S, Mateos M, Bergsagel P, Chesi M, et al.
Blood Cancer Discov
. 2024 Mar;
5(3):146-152.
PMID: 38441243
While the current approach to precursor hematologic conditions is to "watch and wait," this may change with the development of therapies that are safe and extend survival or delay the...
6.
Thorsteinsdottir S, Gislason G, Aspelund T, Rognvaldsson S, Oskarsson J, Sigurdardottir G, et al.
Nat Med
. 2023 Mar;
29(12):3269.
PMID: 36941333
No abstract available.
7.
Thorsteinsdottir S, Gislason G, Aspelund T, Rognvaldsson S, Oskarsson J, Sigurdardottir G, et al.
Nat Med
. 2023 Feb;
29(2):467-472.
PMID: 36747117
Smoldering multiple myeloma (SMM) is an asymptomatic precursor to multiple myeloma. Here we define the epidemiological characteristics of SMM in the general population in Iceland. The iStopMM study (ClinicalTrials.gov ID:...
8.
Steingrimsson V, Lund S, Dickman P, Weibull C, Bjorkholm M, Landgren O, et al.
Eur J Haematol
. 2021 Oct;
108(2):145-153.
PMID: 34714556
Objective: To evaluate temporal trends in survival and causes of death in patients with chronic lymphocytic leukemia (CLL) in a nationwide study. Methods: The cohort consisted of 13,009 Swedish CLL...
9.
Mikaelsdottir E, Thorleifsson G, Stefansdottir L, Halldorsson G, Sigurdsson J, Lund S, et al.
Commun Biol
. 2021 Sep;
4(1):1132.
PMID: 34580418
Platelets play an important role in hemostasis and other aspects of vascular biology. We conducted a meta-analysis of platelet count GWAS using data on 536,974 Europeans and identified 577 independent...
10.
Jonsdottir G, Bjorkholm M, Turesson I, Hultcrantz M, Diamond B, Porwit A, et al.
Eur J Haematol
. 2021 May;
107(2):275-282.
PMID: 33966293
Objectives: The aim of this study was to determine risk factors for development of acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) in patients with multiple myeloma (MM). Methods: We identified all patients...